Tocilizumab

ACTEMRA, AVTOZMA, Actemra ACTPen, TOFIDENCE

Interleukin-6 Receptor Antagonist

NADAC/unit $1279.0578

No Shortage Tier 1: 9.7% PA Req: 51.1%

TOFIDENCE™ (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumato....

vs. brand ACTEMRA: Generic saves up to -12691% per unit

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Tocilizumab drfinder.aiFind doctors who prescribe Tocilizumab rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Tocilizumab

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.